Kenzo Tokunaga

List of Publications by Year
in descending order

82	6,815	147726	74108
papers	citations	31 h-index	75 g-index

90	90	90	8816
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MARCH8: the tie that binds to viruses. FEBS Journal, 2022, 289, 3642-3654.	2.2	8
2	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, 2022, 602, 300-306.	13.7	428
3	MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins. Microbiology Spectrum, 2022, 10, e0061821.	1.2	15
4	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Reports, 2022, 38, 110218.	2.9	148
5	Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature, 2022, 603, 700-705.	13.7	447
6	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	13.7	756
7	SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nature Communications, 2021, 12, 848.	5.8	389
8	Phenotypic and Genotypic Co-receptor Tropism Testing in HIV-1 Epidemic Region of Tanzania Where Multiple Non-B Subtypes Co-circulate. Frontiers in Microbiology, 2021, 12, 703041.	1.5	4
9	Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses. Journal of Virology, 2021, 95, e0063421.	1.5	8
10	SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. Journal of Infectious Diseases, 2021, 224, 989-994.	1.9	136
11	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	13.7	1,041
12	Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag. Journal of Biological Chemistry, 2020, 295, 13023-13030.	1.6	57
13	MARCH8 inhibits viral infection by two different mechanisms. ELife, 2020, 9, .	2.8	37
14	CRISPR-mediated activation of endogenous BST-2/tetherin expression inhibits wild-type HIV-1 production. Scientific Reports, 2019, 9, 3134.	1.6	17
15	Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection. Journal of Biological Chemistry, 2019, 294, 3397-3405.	1.6	43
16	Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase. Journal of Virology, 2017, 91, .	1.5	13
17	Homeostatically Maintained Resting Naive CD4+ T Cells Resist Latent HIV Reactivation. Frontiers in Microbiology, 2016, 7, 1944.	1.5	22
18	An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating. Retrovirology, 2016, 13, 72.	0.9	35

#	Article	IF	Citations
19	Anti-APOBEC3G Activity of HIV-1 Vif Protein Is Attenuated in Elite Controllers. Journal of Virology, 2015, 89, 4992-5001.	1.5	20
20	MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nature Medicine, 2015, 21, 1502-1507.	15.2	112
21	The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway. Virus Research, 2015, 195, 25-34.	1.1	21
22	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Retrovirology, 2014, 11, 32.	0.9	9
23	DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition. Retrovirology, 2013, 10, 21.	0.9	26
24	Membrane-associated RING-CH (MARCH) 8 protein inhibits HIV-1 infection. Retrovirology, 2013, 10, .	0.9	2
25	Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. Microbes and Infection, 2013, 15, 280-290.	1.0	52
26	Membrane-associated RING-CH (MARCH) 8 mediates the ubiquitination and lysosomal degradation of the transferrin receptor. Journal of Cell Science, 2013, 126, 2798-809.	1.2	63
27	APOBEC3G Oligomerization Is Associated with the Inhibition of Both Alu and LINE-1 Retrotransposition. PLoS ONE, 2013, 8, e84228.	1.1	19
28	Transgenic expression of the human LEDGF/p75 gene relieves the species barrier against HIV-1 infection in mouse cells. Frontiers in Microbiology, 2013, 4, 377.	1.5	1
29	Sites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation. Current HIV Research, 2012, 10, 283-291.	0.2	15
30	Intracellular Logistics of BST-2/Tetherin. Current HIV Research, 2012, 10, 321-326.	0.2	8
31	Editorial: HIV-1 Vpu and BST-2/Tetherin: Enemies at the Gates. Current HIV Research, 2012, 10, 275-276.	0.2	0
32	Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology, 2012, 9, 112.	0.9	88
33	Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Frontiers in Microbiology, 2012, 3, 275.	1.5	45
34	Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism. Frontiers in Microbiology, 2011, 2, 250.	1.5	22
35	Identification of SNF2h, a Chromatin-Remodeling Factor, as a Novel Binding Protein of Vpr of Human Immunodeficiency Virus Type 1. Journal of NeuroImmune Pharmacology, 2011, 6, 177-187.	2.1	5
36	Epigenetic displacement of HP1 from heterochromatin by HIV-1 Vpr causes premature sister chromatid separation. Journal of Cell Biology, 2011, 194, 721-735.	2.3	39

#	Article	IF	Citations
37	Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Research, 2011, 39, 5538-5554.	6.5	59
38	Combined analysis of cell growth and apoptosis-regulating proteins in HPVs associated anogenital tumors. BMC Cancer, 2010, 10, 118.	1.1	6
39	The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors. Virology, 2010, 405, 129-138.	1.1	2
40	Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain. Journal of Virology, 2010, 84, 4311-4320.	1.5	35
41	Differential Anti-APOBEC3G Activity of HIV-1 Vif Proteins Derived from Different Subtypes. Journal of Biological Chemistry, 2010, 285, 35350-35358.	1.6	48
42	Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu. Communicative and Integrative Biology, 2010, 3, 366-369.	0.6	14
43	Genotypic Characterization of CRF01_AEenvGenes Derived from Human Immunodeficiency Virus Type 1-Infected Patients Residing in Central Thailand. AIDS Research and Human Retroviruses, 2009, 25, 229-236.	0.5	20
44	HIV-1 Accessory Protein Vpu Internalizes Cell-surface BST-2/Tetherin through Transmembrane Interactions Leading to Lysosomes. Journal of Biological Chemistry, 2009, 284, 35060-35072.	1.6	197
45	Evaluation of telomerase activity in non-genital Bowen's disease. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 668-672.	1.3	2
46	Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes and Infection, 2009, 11, 334-343.	1.0	19
47	Impact of Amino Acid Variations in Gag and Protease of HIV Type 1 CRF01_AE Strains on Drug Susceptibility of Virus to Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 320-328.	0.9	15
48	Inhibitory function of adapter-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome. Virology, 2008, 373, 171-180.	1.1	14
49	Modulation of TNF-Î±-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-Î± production and facilitates viral entry. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7809-7814.	3.3	478
50	All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Research, 2007, 35, 2955-2964.	6.5	182
51	Successful Mouse Cloning of an Outbred Strain by Trichostatin A Treatment after Somatic Nuclear Transfer. Journal of Reproduction and Development, 2007, 53, 165-170.	0.5	141
52	Identification of the suppressive factors for human immunodeficiency virus type-1 replication using the siRNA mini-library directed against host cellular genes. Biochemical and Biophysical Research Communications, 2007, 359, 729-734.	1.0	11
53	HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene, 2007, 26, 477-486.	2.6	50
54	Tristetraprolin inhibits HIV-1 production by binding to genomic RNA. Microbes and Infection, 2006, 8, 2647-2656.	1.0	19

#	Article	IF	Citations
55	HIV-1 Vpr Induces DNA Double-Strand Breaks. Cancer Research, 2006, 66, 627-631.	0.4	69
56	Premature sister chromatid separation in HIV-1-infected peripheral blood lymphocytes. Aids, 2005, 19, 1434-1438.	1.0	6
57	Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor. Journal of Virology, 2005, 79, 5996-6004.	1.5	46
58	Interleukinâ€4 Upâ€Regulates Tâ€Tropic Human Immunodeficiency Virus Type 1 Transcription in Primary CD4⁺ CD38⁺ Tâ€Lymphocyte Subset. Microbiology and Immunology, 2005, 49, 155-165.	0.7	9
59	HIVâ€1 Proteases from Drugâ€Naive West African Patients Are Differentially Less Susceptible to Protease Inhibitors. Clinical Infectious Diseases, 2005, 41, 243-251.	2.9	67
60	Nucleolin and the Packaging Signal, Ï^, Promote the Budding of Human Immunodeficiency Virus Typeâ€1 (HIVâ€1). Microbiology and Immunology, 2004, 48, 111-118.	0.7	22
61	Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2004, 78, 6073-6076.	1.5	416
62	Interleukin-8-mediated Heterologous Receptor Internalization Provides Resistance to HIV-1 Infectivity. Journal of Biological Chemistry, 2003, 278, 15867-15873.	1.6	52
63	Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8442-8447.	3.3	13
64	Requirement of Nef for HIV-1 infectivity is biased by the expression levels of Env in the virus-producing cells and CD4 in the target cells. Archives of Virology, 2001, 146, 1739-1751.	0.9	14
65	Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates. Journal of Virology, 2001, 75, 6776-6785.	1.5	86
66	The Cellular Kinase Binding Motifs (PxxP and RR) in Human Immunodeficiency Virus Type 1 Nef Protein Are Dispensable for Producer-Cell-Dependent Enhancement of Viral Entry. Virology, 1999, 257, 285-289.	1.1	10
67	Producer Cell-Dependent Requirement of the Nef Protein for Efficient Entry of HIV-1 into Cells. Biochemical and Biophysical Research Communications, 1998, 250, 565-568.	1.0	10
68	Enhancement of human immunodeficiency virus type 1 infectivity by Nef is producer cell-dependent.. Journal of General Virology, 1998, 79, 2447-2453.	1.3	25
69	Inhibition of Human Immunodeficiency Virus Type 1 Virion Entry by Dominant-Negative Hck. Journal of Virology, 1998, 72, 6257-6259.	1.5	20
70	Growth ability of auxiliary gene mutants of human immunodeficiency virus types 1 and 2 in unstimulated peripheral blood mononuclear cells. Archives of Virology, 1997, 142, 177-181.	0.9	17
71	Functionality of chimeric Rev proteins of HIV/SIV. Virus Genes, 1995, 11, 11-14.	0.7	2
72	Functional analysis of human spuma retrovirus genome. Virus Genes, 1995, 11, 15-20.	0.7	8

#	Article	IF	Citations
73	Generation and Characterization of a Host Cell-Dependent gag Gene Mutant of Human Immunodeficiency Virus Type 1. Virology, 1995, 212, 251-254.	1.1	17
74	Early replication block of human immunodeficiency virus type 1 in monkey cells. Journal of General Virology, 1995, 76, 2723-2730.	1.3	123
75	Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus. Vaccine, 1995, 13, 1393-1398.	1.7	3
76	Rev-dependency of expression of human immunodeficiency virus type 1gagandenvgenes. FEBS Letters, 1995, 365, 141-145.	1.3	4
77	Superinfection of a Defective Human Immunodeficiency Virus Type 1 Provirus-Carrying T Cell Clone withviforvpuMutants Gives Cytopathic Virus Particles by Homologous Recombination. AIDS Research and Human Retroviruses, 1995, 11, 45-53.	0.5	12
78	Function of human immunodeficiency virus type 1 Vpu protein in various cell types. Journal of General Virology, 1995, 76, 2717-2722.	1.3	52
79	Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells. Journal of Virology, 1995, 69, 7507-7518.	1.5	22
80	Increased anti-HIV-1 activity of CD4 CDR3-related synthetic peptides by scrambling and further structural modifications, includingd-isomerization and dimerization. FEBS Letters, 1993, 330, 117-121.	1.3	5
81	Expression of human immunodeficiency virus type 1 Nef antigen on the surface of acutely and persistently infected human T cells. Vaccine, 1993, 11, 1240-1246.	1.7	31
82	Altered cell tropism and cytopathicity of feline immunodeficiency viruses in two different feline CD4-positive, CD8-negative cell lines. Journal of Virology, 1992, 66, 3893-3898.	1.5	22